Healthcare Providers & Services

TradingKey - CVS Health (CVS) reported earnings that beat market expectations for the eighth consecutive quarter, yet failed to win over investors. On November 4, the company announced plans to split its business into two independent publicly traded companies in the first half of 2028. Following the announcement, its stock plunged 12.5% to a near six-month low.

TradingKey - UnitedHealth heads into October 13 earnings with improving medical costs and Optum margins, but weaker Medicare Star Ratings and regulatory scrutiny add risk.

TradingKey - UnitedHealth beat Q2 2026 EPS by 30%, reported an 86.7% medical cost ratio (down from 89.4%), and raised full-year guidance to $19.50 to $20.00 per share. At $425 in a rising channel, here’s what $454 needs and why the DOJ investigation still matters.

TradingKey - Eli Lilly (LLY) shares rose nearly 2% in Thursday’s pre-market session as the market focused on a major decision from U.S. healthcare giant CVS Health (CVS). CVS announced it would restore insurance coverage for the weight-loss drug Zepbound and include Foundayo, an oral weight-loss medication newly approved in April, in its standard drug formulary.

TradingKey - Wall Street is navigating a two-day inflation gauntlet. Tuesday's CPI print for April arrived hotter than expected, rattling equity markets from telehealth to nuclear energy. Wednesday morning brings the Producer Price Index (PPI) for April — and if today's Consumer Price Index is any g

TradingKey - Hims & Hers Health (HIMS) is due to release its Q1 2026 results after the closing bell today. Below, we outline what investors should watch for in today's report.